Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products. Cialis and Effient reported lower sales during the second quarter.
The above chart shows the revenues for Eli Lilly’s cardiovascular products since the first quarter of 2017.
Cialis is a blockbuster drug from Eli Lilly’s portfolio approved for the treatment of erectile dysfunction and benign prostatic hyperplasia. Cialis reported revenue of ~$538.7 million during the second quarter, a 14% fall compared to $627.3 million in the second quarter of 2017. The fall was driven by lower sales of Cialis both in US markets and outside US markets.
US sales fell 9% to $345.7 million, and sales outside the US fell 22% to $193.0 million during the quarter.
Effient is an antiplatelet approved for use in combination with aspirins for preventing blood clots in arteries and stents, thereby reducing the chances of heart issues. Effient is part of Eli Lilly’s collaboration with Daiichi Sankyo. Eli Lilly holds the marketing rights for US markets, while Daiichi Sankyo holds the marketing rights for European markets and Japan.
Effient reported a YoY fall in revenue to $27.9 million during the second quarter compared to $142.9 million during the second quarter of 2017.
Adcirca, Livalo, and Zalutia are other cardiovascular products from Eli Lilly. The revenue for these other drugs totaled $126.4 million in the second quarter driven by strong growth in US sales and partially offset by lower outside US sales during the quarter.